

Apar Kishor Ganti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8964052/publications.pdf>

Version: 2024-02-01

226
papers

7,859
citations

93792

39
h-index

68831

81
g-index

233
all docs

233
docs citations

233
times ranked

13237
citing authors

#	ARTICLE	IF	CITATIONS
1	Epigenetic landscape of small cell lung cancer: small image of a giant recalcitrant disease. <i>Seminars in Cancer Biology</i> , 2022, 83, 57-76.	4.3	33
2	Reply. <i>Cancer Letters</i> , 2022, 527, 193-194.	3.2	0
3	Novel targeted therapies for advanced non-small lung cancer. <i>Seminars in Oncology</i> , 2022, 49, 326-336.	0.8	9
4	Outcomes following off-site remote chemotherapy administration.. <i>Journal of Clinical Oncology</i> , 2022, 40, 1516-1516.	0.8	3
5	Consolidation nivolumab plus ipilimumab or nivolumab alone following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: BTCRC LUN 16-081.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8509-8509.	0.8	11
6	Comparison of quality of life in patients randomized to high-dose once daily (QD) thoracic radiotherapy (TRT) with standard twice daily (BID) TRT in limited stage small cell lung cancer (LS-SCLC) on CALGB 30610 (Alliance, Sub-study CALGB 70702).. <i>Journal of Clinical Oncology</i> , 2022, 40, 8504-8504.	0.8	2
7	Systemic inflammation is associated with inferior disease control and survival in stage III non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2021, 9, 227-227.	0.7	9
8	RNA-based therapies: A cog in the wheel of lung cancer defense. <i>Molecular Cancer</i> , 2021, 20, 54.	7.9	53
9	Recurrent Cushing Syndrome Secondary to Metastatic Adrenocortical Carcinoma in a Patient With Previously Resected Adenoma. <i>Journal of the Endocrine Society</i> , 2021, 5, A983-A983.	0.1	0
10	ST6GalNAc6S promotes lung cancer metastasis by altering MUC5AC sialylation. <i>Molecular Oncology</i> , 2021, 15, 1866-1881.	2.1	14
11	Characterizing Immune Checkpoint Inhibitor-Induced Hypophysitis and Obstacles in Diagnosis. <i>Journal of the Endocrine Society</i> , 2021, 5, A624-A625.	0.1	0
12	Thyroid Immune-Related Adverse Events Are Associated With Improved Survival in Cancer Patients. <i>Journal of the Endocrine Society</i> , 2021, 5, A847-A848.	0.1	0
13	Dual blockade of EGFR and CDK4/6 delays head and neck squamous cell carcinoma progression by inducing metabolic rewiring. <i>Cancer Letters</i> , 2021, 510, 79-92.	3.2	16
14	Associations of serum cytokines and chemokines with the risk of incident cancer in a prospective rheumatoid arthritis cohort. <i>International Immunopharmacology</i> , 2021, 97, 107719.	1.7	3
15	Update of Incidence, Prevalence, Survival, and Initial Treatment in Patients With Non-Small Cell Lung Cancer in the US. <i>JAMA Oncology</i> , 2021, 7, 1824.	3.4	192
16	Phase II of CD40 agonistic antibody sotigalimab (APX005M) in combination with nivolumab in subjects with metastatic melanoma with confirmed disease progression on anti-PD-1 therapy. , 2021, 9, A422-A422.		6
17	A Comparative Analysis of Survival and Funding Discrepancies in Cancers With High Mortality. <i>Annals of Surgery</i> , 2020, 271, 296-302.	2.1	6
18	A phase I study of weekly doxorubicin and oral topotecan for patients with relapsed or refractory small cell lung cancer (SCLC): A Fred and Pamela Buffet Cancer Center Clinical Trials Network study. <i>Cancer Treatment and Research Communications</i> , 2020, 22, 100162.	0.7	2

#	ARTICLE	IF	CITATIONS
19	Pembrolizumab—the KEY to an evolving landscape in treatment of squamous non-small cell lung cancer (NSCLC). <i>Translational Lung Cancer Research</i> , 2020, 9, 824-827.	1.3	0
20	Differential mutation spectrum and immune landscape in African Americans versus Whites: A possible determinant to health disparity in head and neck cancer. <i>Cancer Letters</i> , 2020, 492, 44-53.	3.2	10
21	Impact of time-to-treatment on overall survival of non-small cell lung cancer patients—an analysis of the national cancer database. <i>Translational Lung Cancer Research</i> , 2020, 9, 1202-1211.	1.3	17
22	Oncology Care Delivery in the COVID-19 Pandemic: An Opportunity to Study Innovations and Outcomes. <i>JCO Oncology Practice</i> , 2020, 16, 431-434.	1.4	12
23	Adjuvant chemotherapy following SBRT for early stage non-small cell lung cancer (NSCLC) in older patients. <i>Journal of Geriatric Oncology</i> , 2020, 11, 1145-1153.	0.5	3
24	Immunotherapy in lung cancer: the chemotherapy conundrum. <i>Chinese Clinical Oncology</i> , 2020, 9, 59-59.	0.4	15
25	Predicting risk of chemotherapy-induced severe neutropenia: A pooled analysis in individual patients data with advanced lung cancer. <i>Lung Cancer</i> , 2020, 141, 14-20.	0.9	9
26	Daily Lisinopril vs Placebo for Prevention of Chemoradiation-Induced Pulmonary Distress in Patients With Lung Cancer (Alliance MC1221): A Pilot Double-Blind Randomized Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 686-696.	0.4	15
27	HPV Status and Survival in Non-Oropharyngeal Squamous Cell Carcinoma of the Head and Neck. <i>Anticancer Research</i> , 2019, 39, 1907-1914.	0.5	32
28	Clinical prognostic model for older patients with advanced non-small cell lung cancer. <i>Journal of Geriatric Oncology</i> , 2019, 10, 555-559.	0.5	6
29	Utilization of the Veterans Affairs Central Cancer Registry to evaluate lung cancer outcomes. <i>Seminars in Oncology</i> , 2019, 46, 321-326.	0.8	4
30	Patient-Defined Treatment Success: Perspectives of Patients With Advanced-Stage Lung Cancer. <i>Journal of Oncology Practice</i> , 2019, 15, e758-e768.	2.5	4
31	Impact of patient symptoms and caregiving tasks on psychological distress in caregivers for head and neck cancer (HNC). <i>Psycho-Oncology</i> , 2019, 28, 511-517.	1.0	19
32	Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in the USA. <i>PLoS ONE</i> , 2019, 14, e0209709.	1.1	41
33	Adjuvant Systemic Therapy in Patients With Early-Stage NSCLC Treated With Stereotactic Body Radiation Therapy. <i>Journal of Thoracic Oncology</i> , 2019, 14, 475-481.	0.5	19
34	A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited-stage small cell lung cancer in elderly patients versus younger patients. <i>Cancer</i> , 2019, 125, 382-390.	2.0	14
35	Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. <i>Lancet</i> , The, 2019, 393, 156-167.	6.3	1,153
36	Interim safety analysis of consolidation nivolumab and ipilimumab versus nivolumab alone following concurrent chemoradiation for unresectable stage IIIA/IIIB NSCLC: Big Ten Cancer Research Consortium LUN 16-081.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8535-8535.	0.8	8

#	ARTICLE	IF	CITATIONS
37	Association Between Treatment Facility Volume, Therapy Types, and Overall Survival in Patients With Stage IIIA Non-Small Cell Lung Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 229-236.	2.3	11
38	Association Between Hospital Volume, Therapy Types, and Overall Survival in Stage III and IV Cutaneous Malignant Melanoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1334-1342.	2.3	7
39	Outcomes following lobectomy and pneumonectomy in stage IIIA non-small cell lung cancer (NSCLC) after neoadjuvant chemoradiation. <i>Journal of Clinical Oncology</i> , 2019, 37, e20042-e20042.	0.8	0
40	Safety of long-term anticoagulation in patients with brain metastases. <i>Medical Oncology</i> , 2018, 35, 43.	1.2	9
41	A prognostic scoring model for survival after locoregional therapy in de novo stage IV breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 677-685.	1.1	7
42	Unclassifiable B-Cell Lymphoma With Symptomatic Hyperleukocytosis Managed With Leukapheresis. <i>Journal of Oncology Practice</i> , 2018, 14, 329-330.	2.5	1
43	Immunotherapy in treatment naïve advanced non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S412-S421.	0.6	13
44	Predictive biomarkers for immune checkpoint inhibitor therapy: we need to keep searching. <i>Journal of Thoracic Disease</i> , 2018, 10, S2195-S2197.	0.6	3
45	Hunting for transcription factors: STAT3 decoy in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, S254-S257.	1.3	2
46	Sequential HER2-Targeted Therapy in Salivary Ductal Carcinoma With HER2/neu Overexpression and a Concomitant ERBB2 Mutation. <i>JCO Precision Oncology</i> , 2018, 2, 1-5.	1.5	1
47	Advanced pancreatic cancer: a meta-analysis of clinical trials over thirty years. <i>Oncotarget</i> , 2018, 9, 19396-19405.	0.8	37
48	NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 1171-1182.	2.3	192
49	Preoperative Pulmonary Function Tests (PFTs) and Outcomes from Resected Early Stage Non-small Cell Lung Cancer (NSCLC). <i>Anticancer Research</i> , 2018, 38, 2903-2907.	0.5	9
50	Predictors of survival after loco-regional therapy (LRT) in stage 4 breast cancer (BC). <i>Journal of Clinical Oncology</i> , 2018, 36, 1083-1083.	0.8	0
51	Association between hospital volume and overall survival (OS) of stage 3 and 4 cutaneous malignant melanoma (MMel). <i>Journal of Clinical Oncology</i> , 2018, 36, 9524-9524.	0.8	0
52	Association between hospital volume, treatment patterns, and overall survival (OS) of patients with stage 3A non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2018, 36, 8543-8543.	0.8	1
53	Postoperative mortality following multimodality therapy for pancreatic cancer: Analysis of the SEER-Medicare data. <i>Journal of Surgical Oncology</i> , 2017, 115, 158-163.	0.8	10
54	MUC16 Regulates TSPYL5 for Lung Cancer Cell Growth and Chemoresistance by Suppressing p53. <i>Clinical Cancer Research</i> , 2017, 23, 3906-3917.	3.2	64

#	ARTICLE	IF	CITATIONS
55	Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials. <i>Oncologist</i> , 2017, 22, 189-198.	1.9	9
56	Lung cancer – A global perspective. <i>Journal of Surgical Oncology</i> , 2017, 115, 550-554.	0.8	72
57	Epidermal Growth Factor Receptor Mutational Status and Brain Metastases in Non-Small-Cell Lung Cancer. <i>Journal of Global Oncology</i> , 2017, 3, 208-217.	0.5	33
58	Access to Cancer Specialist Care and Treatment in Patients With Advanced Stage Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 640-650.e2.	1.1	5
59	Chemoradiotherapy for locally advanced squamous cell carcinoma of the oropharynx: Does completion of systemic therapy affect outcomes?. <i>Oral Oncology</i> , 2017, 73, 105-110.	0.8	9
60	Mortality following pancreatectomy for elderly rural veterans with pancreatic cancer. <i>Journal of Geriatric Oncology</i> , 2017, 8, 284-288.	0.5	8
61	Weekly vinorelbine and paclitaxel in older patients with advanced non-small cell lung cancer: A phase II Fred and Pamela Buffet Cancer Center Clinical Trials Network study. <i>Journal of Geriatric Oncology</i> , 2017, 8, 18-22.	0.5	9
62	Weight Loss and Percutaneous Endoscopic Gastrostomy Tube Placement during Chemoradiotherapy for Locally Advanced Cancer of the Oropharynx Do Not Negatively Impact Outcomes. <i>Frontiers in Oncology</i> , 2017, 7, 299.	1.3	6
63	Surgery for limited-stage small cell lung cancer: ready for prime-time?. <i>Journal of Thoracic Disease</i> , 2017, 9, 3576-3578.	0.6	7
64	HPV status and survival in non-oropharyngeal squamous cell carcinoma of the head and neck.. <i>Journal of Clinical Oncology</i> , 2017, 35, 6046-6046.	0.8	2
65	Efficacy and safety of anti-VEGF therapy in metastatic unresectable hepatocellular carcinoma: A meta-analysis.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15632-e15632.	0.8	1
66	Afatinib radiosensitizes head and neck squamous cell carcinoma cells by targeting cancer stem cells. <i>Oncotarget</i> , 2017, 8, 20961-20973.	0.8	41
67	Bevacizumab in extensive-disease small cell lung cancer: the search continues. <i>Translational Cancer Research</i> , 2017, 6, S537-S538.	0.4	0
68	Clinical behavior of stage IVC squamous cell carcinoma of the head and neck.. <i>Journal of Clinical Oncology</i> , 2017, 35, e17511-e17511.	0.8	0
69	What's New in Head and Neck Cancer: Key Findings in 2015 – 2016 From ECCO/ESMO, ASTRO, and the Multidisciplinary Head and Neck Cancer Symposium. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, 176-183.	1.8	2
70	Resected small cell lung cancer – time for more?. <i>Journal of Thoracic Disease</i> , 2016, 8, E755-E757.	0.6	0
71	Resected small cell lung cancer – what do we do next?. <i>Annals of Translational Medicine</i> , 2016, 4, 288-288.	0.7	2
72	Effect of Surgical Intervention on Survival of Patients With Clinical N2 Non-Small Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 142-146.	0.6	3

#	ARTICLE	IF	CITATIONS
73	Associations of Circulating Cytokines and Chemokines With Cancer Mortality in Men With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 2394-2402.	2.9	17
74	NCCN Guidelines Insights: Older Adult Oncology, Version 2.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1357-1370.	2.3	82
75	Concurrent chemoradiotherapy in older adults with squamous cell head & neck cancer: Evidence and management. <i>Journal of Geriatric Oncology</i> , 2016, 7, 145-153.	0.5	10
76	Nasopharyngeal carcinoma in pregnancy: A case series and literature review. <i>Cancer Treatment and Research Communications</i> , 2016, 9, 126-130.	0.7	0
77	Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012. <i>Journal of Clinical Oncology</i> , 2016, 34, 3992-3999.	0.8	87
78	Anaplastic Thyroid Carcinoma: Light at the End of the Tunnel?. <i>Journal of Oncology Practice</i> , 2016, 12, 519-520.	2.5	2
79	Activity of single-agent decitabine in atypical chronic myeloid leukemia. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 790-794.	0.5	22
80	Early Stage Non-Small-Cell Lung Cancer in Octogenarian and Older Patients: A SEER Database Analysis. <i>Clinical Lung Cancer</i> , 2016, 17, 285-291.	1.1	22
81	Multimodality Therapy for Limited-Stage Small-Cell Lung Cancer. <i>Journal of Oncology Practice</i> , 2016, 12, 111-117.	2.5	16
82	MUC5AC interactions with integrin $\alpha 4$ enhances the migration of lung cancer cells through FAK signaling. <i>Oncogene</i> , 2016, 35, 4112-4121.	2.6	68
83	EGFR monoclonal antibodies in locally advanced head and neck squamous cell carcinoma: What is their current role?. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 170-179.	2.0	18
84	Emerging targeted therapies in non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 177-187.	1.1	9
85	Coping with an Advanced Stage Lung Cancer Diagnosis: Patient, Caregiver, and Provider Perspectives on the Role of the Health Care System. <i>Journal of Cancer Education</i> , 2016, 31, 554-558.	0.6	7
86	Complications of anticoagulant therapy in patients with brain metastases.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2078-2078.	0.8	1
87	Effect of time to treatment on survival in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8542-8542.	0.8	4
88	Effect of weight loss during concurrent chemoradiation on outcomes of oropharyngeal cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, e17541-e17541.	0.8	1
89	Effect of EGFR mutations on outcomes in NSCLC with brain metastases.. <i>Journal of Clinical Oncology</i> , 2016, 34, e20644-e20644.	0.8	1
90	Late-stage lung cancer patient preferences about chemotherapy treatment adverse side effects.. <i>Journal of Clinical Oncology</i> , 2016, 34, 93-93.	0.8	0

#	ARTICLE	IF	CITATIONS
91	Non-“small cell lung cancer in veterans: Disparities in prevalence and survival among different histologic subtypes.. Journal of Clinical Oncology, 2016, 34, e20590-e20590.	0.8	3
92	Access to biomarker testing in patients with advanced non-small cell lung cancer.. Journal of Clinical Oncology, 2016, 34, e20655-e20655.	0.8	0
93	Access to specialist care and treatment in patients with advanced non-small cell lung cancer.. Journal of Clinical Oncology, 2016, 34, 9094-9094.	0.8	0
94	Impact of adjuvant chemotherapy on outcomes in stage IB non-small cell lung cancer.. Journal of Clinical Oncology, 2016, 34, e20002-e20002.	0.8	0
95	Relapsed small cell lung cancer: is more better?. Translational Cancer Research, 2016, 5, S1363-S1365.	0.4	0
96	Effect of age on the efficacy of adjuvant chemotherapy for resected non-“small cell lung cancer. Cancer, 2015, 121, 2578-2585.	2.0	31
97	Renal Toxicities of Targeted Therapies. Targeted Oncology, 2015, 10, 487-499.	1.7	66
98	Treatment-related acute myeloid leukemia in a chronic lymphocytic leukemia patient: role of fludarabine?. Therapeutic Advances in Hematology, 2015, 6, 88-92.	1.1	2
99	Treatment of advanced thyroid cancer: role of molecularly targeted therapies. Targeted Oncology, 2015, 10, 311-324.	1.7	20
100	Comorbidity and Survival in Lung Cancer Patients. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1079-1085.	1.1	140
101	Effect of smoking on survival from non-small cell lung cancer: a retrospective Veteransâ€™ Affairs Central Cancer Registry (VACCR) cohort analysis. Medical Oncology, 2015, 32, 339.	1.2	12
102	Mucins in Lung Cancer: Diagnostic, Prognostic, and Therapeutic Implications. Journal of Thoracic Oncology, 2015, 10, 19-27.	0.5	110
103	Clinicopathologic characteristics and management trends of cutaneous invasive and <i>in situ</i> melanoma in older patients: a retrospective analysis of the National Cancer Data Base. Therapeutic Advances in Medical Oncology, 2015, 7, 4-11.	1.4	12
104	Validation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups. Lung Cancer, 2015, 90, 281-287.	0.9	6
105	MUC4 regulates cellular senescence in head and neck squamous cell carcinoma through p16/Rb pathway. Oncogene, 2015, 34, 1698-1708.	2.6	28
106	Conditional survival estimates for small cell lung cancer receiving prophylactic cranial irradiation in the U.S. (1988-1997).. Journal of Clinical Oncology, 2015, 33, 7577-7577.	0.8	2
107	Targeting EGF-receptor(s) - STAT1 axis attenuates tumor growth and metastasis through downregulation of MUC4 mucin in human pancreatic cancer. Oncotarget, 2015, 6, 5164-5181.	0.8	42
108	Novel HER3/MUC4 oncogenic signaling aggravates the tumorigenic phenotypes of pancreatic cancer cells. Oncotarget, 2015, 6, 21085-21099.	0.8	31

#	ARTICLE	IF	CITATIONS
109	Characteristics of Extensive Stage Small Cell Lung Cancer: A National Cancer Database Review.. Journal of Clinical Oncology, 2015, 33, e17590-e17590.	0.8	0
110	Effect of demographic factors and histology on stage IV non-small cell lung cancer (NSCLC): A National Cancer Database review.. Journal of Clinical Oncology, 2015, 33, 6558-6558.	0.8	0
111	A Multicenter Pilot Study Examining the Role of Circulating Tumor Cells as a Blood-Based Tumor Marker in Patients with Extensive Small-Cell Lung Cancer. Frontiers in Oncology, 2014, 4, 271.	1.3	30
112	Sorafenib in squamous cell carcinoma of the head and neck: molecular basis and potential role. Future Oncology, 2014, 10, 17-20.	1.1	2
113	Safety and efficacy of preoperative sorafenib therapy in facilitating cytoreductive surgery in renal cell carcinoma. Future Oncology, 2014, 10, 703-706.	1.1	4
114	Author's response to "Country of origin and breast cancer survival". Asia-Pacific Journal of Clinical Oncology, 2014, 10, 280-280.	0.7	0
115	Association Between Race and Survival of Patients With Non-Small-Cell Lung Cancer in the United States Veterans Affairs Population. Clinical Lung Cancer, 2014, 15, 152-158.	1.1	38
116	Smoking and microRNA dysregulation: a cancerous combination. Trends in Molecular Medicine, 2014, 20, 36-47.	3.5	65
117	Novel role of pancreatic differentiation 2 in facilitating self-renewal and drug resistance of pancreatic cancer stem cells. British Journal of Cancer, 2014, 111, 486-496.	2.9	37
118	Engaging Patients and Caregivers in Patient-Centered Outcomes Research on Advanced Stage Lung Cancer: Insights from Patients, Caregivers, and Providers. Journal of Cancer Education, 2014, 29, 796-801.	0.6	12
119	Use and impact of adjuvant chemotherapy in patients with resected non-small cell lung cancer. Cancer, 2014, 120, 1939-1947.	2.0	34
120	Human papilloma virus positive oropharyngeal squamous cell carcinoma: A growing epidemic. Cancer Treatment Reviews, 2014, 40, 215-219.	3.4	74
121	Breast cancer survival of Hispanic women in the USA is influenced by country of origin. Asia-Pacific Journal of Clinical Oncology, 2014, 10, 124-132.	0.7	4
122	Senior Adult Oncology, Version 2.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 82-126.	2.3	116
123	Management of Patients With Lung Cancer and Poor Performance Status. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1015-1025.	2.3	20
124	Ipilimumab-Induced Hypophysitis and Uveitis in a Patient With Metastatic Melanoma and a History of Ipilimumab-Induced Skin Rash. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1077-1081.	2.3	66
125	Exertional Chest Pain and Dyspnea From Hyperviscosity Syndrome Related to Marginal Zone Lymphoma. World Journal of Oncology, 2014, 5, 175-177.	0.6	0
126	Clinicopathologic characteristics and management trends of cutaneous melanoma among older patients: A National Cancer Data Base (NCDB) analysis.. Journal of Clinical Oncology, 2014, 32, 9059-9059.	0.8	0

#	ARTICLE	IF	CITATIONS
127	Outcomes following surgical treatment compared to radiation for stage I NSCLC: A SEER database analysis. <i>Lung Cancer</i> , 2013, 82, 90-94.	0.9	13
128	Combination therapy with bevacizumab and temsirolimus in squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2013, 49, e25.	0.8	1
129	Holy Basil leaf extract decreases tumorigenicity and metastasis of aggressive human pancreatic cancer cells in vitro and in vivo: Potential role in therapy. <i>Cancer Letters</i> , 2013, 336, 270-280.	3.2	37
130	Factors affecting the development of atrial fibrillation and atrial flutter (AF/AFL) following autologous hematopoietic SCT (auto-HSCT). <i>Bone Marrow Transplantation</i> , 2013, 48, 963-965.	1.3	12
131	Salivary duct carcinoma responding to trastuzumab-based therapy: Case report and review of the literature. <i>Head and Neck</i> , 2013, 35, E372-5.	0.9	31
132	Brain Metastasis in Patients With Non-Small-Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations. <i>Journal of Clinical Oncology</i> , 2013, 31, 3162-3164.	0.8	36
133	Pathobiological Implications of MUC4 in Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, 398-407.	0.5	38
134	Small Cell Lung Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 78-98.	2.3	331
135	Profile of vismodegib and its potential in the treatment of advanced basal cell carcinoma. <i>Cancer Management and Research</i> , 2013, 5, 197.	0.9	22
136	Utilization and impact of adjuvant chemotherapy (AC) in surgically resected stages I-III non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 7538-7538.	0.8	0
137	Current concepts in the management of small cell lung cancer. <i>Indian Journal of Medical Research</i> , 2013, 137, 1043-51.	0.4	4
138	Senior Adult Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 162-209.	2.3	105
139	Treatment of Non-Small Cell Lung Cancer in the Older Patient. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 230-239.	2.3	26
140	The Management of Patients With Stage IIIA Non-Small Cell Lung Cancer With N2 Mediastinal Node Involvement. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 599-613.	2.3	65
141	Graviola: A novel promising natural-derived drug that inhibits tumorigenicity and metastasis of pancreatic cancer cells in vitro and in vivo through altering cell metabolism. <i>Cancer Letters</i> , 2012, 323, 29-40.	3.2	139
142	Targeting the EGFR signaling pathway in cancer therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, 15-31.	1.5	688
143	Management of squamous cell carcinoma of the head and neck in the elderly: Review and recommendations. <i>Journal of Geriatric Oncology</i> , 2012, 3, 265-272.	0.5	2
144	Malignant Pleural Mesothelioma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 26-41.	2.3	45

#	ARTICLE	IF	CITATIONS
145	Assessment of prognostic factors after primary tumor resection in metastatic colon cancer patients: A Veteran's Affairs Central Cancer Registry (VACCR) analysis, 1995-2008. <i>Journal of Surgical Oncology</i> , 2012, 106, 486-490.	0.8	15
146	Apparent heparin resistance in a patient with infective endocarditis secondary to elevated factor VIII levels. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 34, 132-134.	1.0	24
147	Hemodynamic collapse following bilateral knee arthroplasty: a mysterious case. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 33, 3-5.	1.0	3
148	A comparison of chemotherapy use in stage IV pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 257-257.	0.8	3
149	Surgery and chemoradiotherapy in stage II and III esophageal cancer: A retrospective analysis of first-course treatment across different insurances using the NCDB.. <i>Journal of Clinical Oncology</i> , 2012, 30, 29-29.	0.8	0
150	Statins Use and Risk for Brain Metastasis From Lung Cancer. <i>Cancer Investigation</i> , 2011, 29, 68-72.	0.6	6
151	Systemic therapy for disseminated basal cell carcinoma: An uncommon manifestation of a common cancer. <i>Cancer Treatment Reviews</i> , 2011, 37, 440-443.	3.4	47
152	Role of chemotherapy in the very elderly patients with metastatic pancreatic cancer - A Veterans Affairs Cancer Registry analysis. <i>Journal of Geriatric Oncology</i> , 2011, 2, 209-214.	0.5	22
153	Small Cell Lung Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 1086-1113.	2.3	29
154	Small lymphocytic lymphoma in a patient with CREST syndrome. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2011, 4, 132-135.	0.6	4
155	Pulmonary toxicities from targeted therapies: a review. <i>Targeted Oncology</i> , 2011, 6, 235-243.	1.7	94
156	Clinicopathologic factors associated with lymph node retrieval in resectable colon cancer: A veterans' affairs central cancer registry (VACCR) database analysis. <i>Journal of Surgical Oncology</i> , 2011, 104, 667-671.	0.8	27
157	Targeted anti-cancer therapy in the elderly. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 78, 227-242.	2.0	33
158	Effect of Palliative Care Services on the Aggressiveness of End-of-Life Care in the Veteran's Affairs Cancer Population. <i>Journal of Palliative Medicine</i> , 2011, 14, 1231-1235.	0.6	70
159	Predictive Ability of Charlson Comorbidity Index on Outcomes From Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 593-596.	0.6	37
160	Lung cancer management in 2010. <i>Oncology</i> , 2011, 25, 64-73.	0.4	12
161	Non-Small Cell Lung Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, 740-801.	2.3	606
162	Clinicopathologic characteristics of primary pleural epithelioid hemangioendothelioma. <i>Oncology Reviews</i> , 2010, 4, 219-222.	0.8	4

#	ARTICLE	IF	CITATIONS
163	Lung cancer in women: role of estrogens. <i>Expert Review of Respiratory Medicine</i> , 2010, 4, 509-518.	1.0	54
164	Epidermal Growth Factor Receptor Signaling in Nonsmall Cell Lung Cancer. <i>Cancer Investigation</i> , 2010, 28, 515-525.	0.6	20
165	Factors affecting bone marrow toxicity following administration of carboplatin and paclitaxel in patients with non-small cell lung cancer. <i>Anticancer Research</i> , 2010, 30, 1365-9.	0.5	6
166	Current concepts in the diagnosis and management of small-cell lung cancer. <i>Oncology</i> , 2010, 24, 1034-9.	0.4	7
167	Selaciclib in malignancies. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1957-1965.	1.9	50
168	Cetuximab in hemodialysis: A case report. <i>Head and Neck</i> , 2009, 31, 1647-1650.	0.9	15
169	Therapeutic options for elderly patients with advanced non-small cell lung cancer. <i>Cancer Treatment Reviews</i> , 2009, 35, 340-344.	3.4	24
170	Association of positive family history with survival of patients with lung cancer. <i>Lung Cancer</i> , 2009, 63, 136-139.	0.9	11
171	Third generation triplet cytotoxic chemotherapy in advanced non-small cell lung cancer: A systematic overview. <i>Lung Cancer</i> , 2009, 64, 194-198.	0.9	36
172	Another nail in the coffin for hormone-replacement therapy?. <i>Lancet, The</i> , 2009, 374, 1217-1218.	6.3	12
173	EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab. <i>Biologics: Targets and Therapy</i> , 2009, 3, 215-24.	3.0	25
174	Outcomes After Hematopoietic Stem-Cell Transplantation for Hematologic Malignancies in Patients With or Without Advance Care Planning. <i>Journal of Clinical Oncology</i> , 2007, 25, 5643-5648.	0.8	49
175	Treatment options for relapsed small-cell lung cancer. <i>Anti-Cancer Drugs</i> , 2007, 18, 255-261.	0.7	12
176	Pancytopenia due to iron deficiency worsened by iron infusion: a case report. <i>Journal of Medical Case Reports</i> , 2007, 1, 175.	0.4	21
177	Comparison of resource utilization and clinical outcomes between teaching and nonteaching medical services. <i>Journal of Hospital Medicine</i> , 2007, 2, 150-157.	0.7	39
178	Hematopoietic stem cell transplantation for Hodgkin's disease in a patient with dysfibrinogenemia and thrombosis. <i>Journal of Thrombosis and Thrombolysis</i> , 2007, 23, 155-158.	1.0	2
179	Targeted therapy for small cell lung cancer. <i>Targeted Oncology</i> , 2007, 2, 89-97.	1.7	2
180	Limited-stage small-cell lung cancer: therapeutic options. <i>Oncology</i> , 2007, 21, 303-12; discussion 312, 315-8, 323.	0.4	5

#	ARTICLE	IF	CITATIONS
181	Targeted therapy in advanced non-small cell lung cancer (NSCLC): Where do we stand?. <i>Cancer Treatment Reviews</i> , 2006, 32, 630-636.	3.4	29
182	Iodine-Refractory Thyroid Carcinoma. <i>Reviews on Recent Clinical Trials</i> , 2006, 1, 133-141.	0.4	5
183	Effect of Diabetes Mellitus on the Epidemiology and Outcomes of Colon Cancer. <i>Medical Oncology</i> , 2006, 23, 515-520.	1.2	26
184	Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group Experience. <i>Annals of Oncology</i> , 2006, 17, 920-927.	0.6	63
185	Adjuvant chemotherapy for early-stage non-small cell lung cancer: the past, the present and the future. <i>Expert Opinion on Biological Therapy</i> , 2006, 6, 709-716.	1.4	4
186	Hormone Replacement Therapy Is Associated With Decreased Survival in Women With Lung Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 59-63.	0.8	186
187	Lung Cancer Screening. <i>Oncologist</i> , 2006, 11, 481-487.	1.9	41
188	Vincristine-laden platelet transfusion for patients with refractory thrombocytopenia. <i>In Vivo</i> , 2006, 20, 559-63.	0.6	2
189	Letters to the editor. <i>Journal of General Internal Medicine</i> , 2005, 20, 377-378.	1.3	1
190	Successful hematopoietic stem-cell transplantation in multicentric Castleman disease complicated by POEMS syndrome. <i>American Journal of Hematology</i> , 2005, 79, 206-210.	2.0	53
191	Lung cancer screening: panacea or pipe dream?. <i>Annals of Oncology</i> , 2005, 16, ii215-ii219.	0.6	17
192	Epidermal growth factor inhibition in solid tumours. <i>Expert Opinion on Biological Therapy</i> , 2005, 5, 1165-1174.	1.4	18
193	HER-2/neu and CD117 (c-kit) overexpression in patients with pesticide exposure and extensive stage small cell lung carcinoma (ESSCLC). <i>Journal of Carcinogenesis</i> , 2005, 4, 8.	2.5	8
194	Hematopoietic stem cell transplantation in mantle cell lymphoma. <i>Annals of Oncology</i> , 2005, 16, 618-624.	0.6	71
195	Outcomes Following Hematopoietic Stem Cell Transplantation for Hematologic Malignancies in Patients with or without Advanced Care Planning.. <i>Blood</i> , 2005, 106, 2025-2025.	0.6	2
196	Follicular lymphoma: expanding therapeutic options. <i>Oncology</i> , 2005, 19, 213-28; discussion 228, 233-6, 239.	0.4	12
197	Survival in untreated early stage non-small cell lung cancer. <i>Anticancer Research</i> , 2005, 25, 3517-20.	0.5	24
198	Determination of vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role of overexpression in leiomyosarcoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2004, 130, 52-56.	1.2	80

#	ARTICLE	IF	CITATIONS
199	Clinical course of lung cancer in patients with chronic kidney disease. Lung Cancer, 2004, 43, 297-300.	0.9	20
200	Patients with Follicular Lymphoma, Grade 3, Have a Prolonged Relapse-Free Survival Following Aggressive Combination Chemotherapy.. Blood, 2004, 104, 613-613.	0.6	1
201	Vincristine-Laden Platelets Can Improve Platelet Counts in Patients with Refractory Thrombocytopenia.. Blood, 2004, 104, 3640-3640.	0.6	0
202	Combined Chemotherapy and Radiation Is Associated with Improved Outcomes in Stage I Follicular Lymphoma.. Blood, 2004, 104, 4567-4567.	0.6	0
203	Immunohistochemical detection of HER-2/neu, c-kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas. Anticancer Research, 2004, 24, 333-7.	0.5	29
204	Risk-Awareness of Cutaneous Malignancies Among Rural Populations. Medical Oncology, 2003, 20, 369-374.	1.2	9
205	Angiosarcoma of the Small Intestine: A Possible Role for Thalidomide?. Medical Oncology, 2003, 20, 397-402.	1.2	24
206	Chromosomal anomalies in two coexistent myeloproliferative disorders. Cancer Genetics and Cytogenetics, 2003, 145, 172-175.	1.0	11
207	Myeloproliferative syndromes and the associated risk of coronary artery disease. Thrombosis Research, 2003, 110, 83-86.	0.8	16
208	Endothelium and the lipid metabolism: the current understanding. International Journal of Cardiology, 2003, 88, 1-9.	0.8	42
209	HER-2/neu Overexpression detected by Immunohistochemistry in Soft Tissue Sarcomas. American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, 188-191.	0.6	11
210	HER-2/neu Overexpression detected by Immunohistochemistry in Soft Tissue Sarcomas. American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, 188-191.	0.6	9
211	Uncommon Syndromes and Treatment Manifestations of Malignancy. Journal of Clinical Oncology, 2003, 21, 168-170.	0.8	54
212	HER-2/neu and CD117 (C-kit) overexpression in hepatocellular and pancreatic carcinoma. Anticancer Research, 2003, 23, 2671-4.	0.5	28
213	Effect of pesticide exposure on HER-2/neu overexpression seen in patients with extensive stage small cell lung carcinoma. Clinical Cancer Research, 2003, 9, 4872-6.	3.2	6
214	Immunohistochemical Identification of HER-2/ neu Overexpression and CD117 (c-kit) Expression in Multiple Myeloma. Leukemia and Lymphoma, 2002, 43, 2427-2430.	0.6	10
215	Role of helicobacter pylori infection in the incidence and clinical course of monoclonal gammopathy of undetermined significance. American Journal of Gastroenterology, 2002, 97, 1371-1374.	0.2	33
216	Immunoglobulin and T-cell Receptor Gene-Gene Rearrangement in Pleural Cavity-based T-cell Rich B-cell Lymphoma in an Immunocompetent Patient. Leukemia and Lymphoma, 2002, 43, 195-198.	0.6	5

#	ARTICLE	IF	CITATIONS
217	Amiodarone-induced Thyrotoxicosis Presenting as Hypokalemic Periodic Paralysis. Southern Medical Journal, 2002, 95, 1326-1328.	0.3	17
218	Plasma Tissue Plasminogen Activator and Plasminogen Activator Inhibitor-1 Levels in Acute Myocardial Infarction. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2002, 32, 80-84.	0.5	14
219	Study of Circadian Variation in the Efficacy of Aspirin as an Analgesic Agent in Experimental Animals. Biological Rhythm Research, 2002, 33, 333-338.	0.4	1
220	Predictive role of HER-2/neu overexpression and clinical features at initial presentation in patients with extensive stage small cell lung carcinoma. Lung Cancer, 2002, 36, 257-261.	0.9	44
221	Thrombocytopenia associated with c7E3 Fab (abciximab). Annals of Hematology, 2002, 81, 76-79.	0.8	18
222	Predictive Value of Clinical Features at Initial Presentation in Pancreatic Adenocarcinoma : A Series of 308 Cases. Medical Oncology, 2002, 19, 233-238.	1.2	23
223	Immunohistochemical detection of C-kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in mantle cell lymphoma. Anticancer Research, 2002, 22, 2899-901.	0.5	31
224	Amiodarone-induced thyrotoxicosis presenting as hypokalemic periodic paralysis. Southern Medical Journal, 2002, 95, 1326-8.	0.3	7
225	Identification of HER-2/neu overexpression and the clinical course of lung carcinoma in non-smokers with chronic lymphocytic leukemia. Lung Cancer, 2001, 34, 227-232.	0.9	17
226	EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab. Biologics: Targets and Therapy, 0, , 215.	3.0	12